Table 2.

Pharmacokinetic parameters of tezosentan following i.v. infusion.

	Study A 100 mg h−1 (6 h)	Study B 5 mg h−1 (72 h)
Number of subjects	6	8
Cmax (µg ml−1)	3.4 (2.7, 4.2)	0.16 (0.12, 0.21)
t1/2,λ1 (h)	0.10 (0.07, 0.15)	–
t1/2,λz (h)	3.2 (2.1, 5.0)	–
AUC(0, ∞) (µg ml−1 h)	16 (13, 20)	7.9 (5.6, 11)a
CL (l h−1)	38 (31, 47)	44 (33, 60)
Vss (l)	22 (14, 36)	–

Data are presented as geometric mean (95% confidence interval).

^aAUC(0, 72 h) (n = 7).